Stock Track | Penumbra Soars 5.66% After-Hours on Strong Q2 Results and Raised Outlook

Stock Track

Jul 30, 2025

Penumbra Inc. (NYSE: PEN) saw its stock surge 5.66% in after-hours trading on Tuesday following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year revenue guidance.

The medical device company reported Q2 revenue of $339.5 million, representing a 13.4% increase from the same period last year and surpassing the analyst consensus estimate of $327.7 million. Penumbra's adjusted earnings per share came in at $0.86, beating the expected $0.82. The company's performance was particularly strong in the U.S. market, with thrombectomy revenue growing by 22.6% and vascular thrombectomy embolization (VTE) revenue surging by 42% compared to the previous year.

Adding to investor optimism, Penumbra raised its full-year 2025 revenue guidance to a range of $1.355 billion to $1.370 billion, indicating an anticipated growth of 13% to 15% over 2024 revenue. The company also maintained its forecast for U.S. thrombectomy growth at 20% to 21% compared to 2024 levels. This positive outlook, combined with the strong quarterly performance, likely contributed to the significant after-hours stock price increase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1168417523"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1168417523\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1168417523?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-30 04:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168417523","market":"us","top_or_hot":-1,"title":"Stock Track | Penumbra Soars 5.66% After-Hours on Strong Q2 Results and Raised Outlook","media":"Stock Track","content":"<p>Penumbra Inc. (NYSE: PEN) saw its stock surge 5.66% in after-hours trading on Tuesday following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year revenue guidance.</p>\n\n<p>The medical device company reported Q2 revenue of $339.5 million, representing a 13.4% increase from the same period last year and surpassing the analyst consensus estimate of $327.7 million. Penumbra's adjusted earnings per share came in at $0.86, beating the expected $0.82. The company's performance was particularly strong in the U.S. market, with thrombectomy revenue growing by 22.6% and vascular thrombectomy embolization (VTE) revenue surging by 42% compared to the previous year.</p>\n\n<p>Adding to investor optimism, Penumbra raised its full-year 2025 revenue guidance to a range of $1.355 billion to $1.370 billion, indicating an anticipated growth of 13% to 15% over 2024 revenue. The company also maintained its forecast for U.S. thrombectomy growth at 20% to 21% compared to 2024 levels. This positive outlook, combined with the strong quarterly performance, likely contributed to the significant after-hours stock price increase.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Penumbra Soars 5.66% After-Hours on Strong Q2 Results and Raised Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Penumbra Soars 5.66% After-Hours on Strong Q2 Results and Raised Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-07-30 04:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Penumbra Inc. (NYSE: PEN) saw its stock surge 5.66% in after-hours trading on Tuesday following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year revenue guidance.</p>\n\n<p>The medical device company reported Q2 revenue of $339.5 million, representing a 13.4% increase from the same period last year and surpassing the analyst consensus estimate of $327.7 million. Penumbra's adjusted earnings per share came in at $0.86, beating the expected $0.82. The company's performance was particularly strong in the U.S. market, with thrombectomy revenue growing by 22.6% and vascular thrombectomy embolization (VTE) revenue surging by 42% compared to the previous year.</p>\n\n<p>Adding to investor optimism, Penumbra raised its full-year 2025 revenue guidance to a range of $1.355 billion to $1.370 billion, indicating an anticipated growth of 13% to 15% over 2024 revenue. The company also maintained its forecast for U.S. thrombectomy growth at 20% to 21% compared to 2024 levels. This positive outlook, combined with the strong quarterly performance, likely contributed to the significant after-hours stock price increase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PEN","symbol_name":"Penumbra Inc","start_time":0,"source_url":"","article_id":"1168417523","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168417523","pubTimestamp":1753821148,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Penumbra Inc. (NYSE: PEN) saw its stock surge 5.66% in after-hours trading on Tuesday following the release of its impressive second-quarter 2025 financial results and an upward revision of its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PEN":"Penumbra Inc"},"translate_title":"个股追踪|Penumbra盘后飙升5.66%，Q2业绩强劲，展望上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEN":1},"content_text":"Penumbra Inc. (NYSE: PEN) saw its stock surge 5.66% in after-hours trading on Tuesday following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year revenue guidance.\nThe medical device company reported Q2 revenue of $339.5 million, representing a 13.4% increase from the same period last year and surpassing the analyst consensus estimate of $327.7 million. Penumbra's adjusted earnings per share came in at $0.86, beating the expected $0.82. The company's performance was particularly strong in the U.S. market, with thrombectomy revenue growing by 22.6% and vascular thrombectomy embolization (VTE) revenue surging by 42% compared to the previous year.\nAdding to investor optimism, Penumbra raised its full-year 2025 revenue guidance to a range of $1.355 billion to $1.370 billion, indicating an anticipated growth of 13% to 15% over 2024 revenue. The company also maintained its forecast for U.S. thrombectomy growth at 20% to 21% compared to 2024 levels. This positive outlook, combined with the strong quarterly performance, likely contributed to the significant after-hours stock price increase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}